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The human malaria parasite Plasmodium falciparum is responsible for the deaths of more than a million
peopleeachyear.FosmidomycinhasbeenproventobeefficientinthetreatmentofP.falciparummalariaby
inhibiting 1-deoxy-D-xylulose 5-phosphate reductoisomerase (DXR), an enzyme of the non-mevalonate
pathway,whichisabsentinhumans.However,thestructuraldetailsofDXRinhibitionbyfosmidomycinin
P. falciparum are unknown. Here, we report the crystal structures of fosmidomycin-bound complete
quaternary complexes of PfDXR. Our study revealed that (i) an intrinsic flexibility of the PfDXR molecule
accounts for an induced-fit movement to accommodate the bound inhibitor in the active site and (ii) a cis
arrangement of the oxygen atoms of the hydroxamate group of the bound inhibitor is essential for tight
binding of the inhibitor to the active site metal. We expect the present structures to be useful guides for the
design of more effective antimalarial compounds.
M
alaria is one of the most widespread infectious diseases, with approximately 500 million cases and more
thanonemilliondeathsperyear
1.Humanmalariaiscausedbyaninfectionwithintracellularparasitesof
the genus Plasmodium that are transmitted by Anopheles mosquitoes
2. Plasmodium falciparum is the
most lethal of the four species of Plasmodium that infect humans. P. falciparum has become highly resistant to a
wide variety of antimalarial drugs, such as chloroquine, amodiaquine, and sulphadoxine-pyrimethamine. New
antimalarial drugs with novel modes of action are urgently needed for the treatment of multidrug-resistant
P. falciparum malaria.
The isoprenoid precursors isopentenyl diphosphate and dimethylallyl diphosphate are synthesised by either
the classical mevalonate pathway or the newly discovered nonmevalonate pathway (the 1-deoxy-D-xylulose
5-phosphate (DOXP) pathway, also called the 2-C-methyl-D-erythritol 4-phosphate (MEP) pathway). The
DOXPpathwayhasbeendetectedineubacteria,higherplants,algae,cyanobacteria,anddiatoms
3,4.Thispathway
is also present in the apicoplast of P. falciparum
5. The DOXP pathway is an ideal target for the development of
herbicidesandantibacterialdrugsbecauseitisessentialforplants,eubacteria
6–8,andprotozoa
9,butitisnotfound
in animals.
The second enzyme of the DOXP pathway, DOXP reductoisomerase (DXR; EC 1.1.1.267), catalyses the
NADPH- and divalent cation (Mg
21 or Mn
21)-dependent transformation of DOXP into MEP
10,11. Shortly after
the discovery of DXR, it was reported that the antibiotic fosmidomycin [3-(N-formyl-N-hydroxyamino)propyl-
phosphonate], originally isolated from Streptomyces lavendulae, was a potent inhibitor of this enzyme (Fig. 1)
12.
In 1999, Jomaa and co-workers reported that fosmidomycin and FR900098 (an N-acetyl derivative of fosmido-
mycin) were able to (1) inhibit the enzymatic activity of recombinant DXR from P. falciparum (PfDXR), (2)
suppress the growth of P. falciparum in culture, and (3) cure mice infected with a related malaria parasite,
Plasmodium vinckei
5. These data established that PfDXR is a promising anti-malarial target. Clinical phase II
trials using fosmidomycin alone or in combination with clindamycin conducted in Gabon and Thailand demon-
strated that PfDXR is an effective target of the chemotherapy used to treat uncomplicated malaria
13–15. However,
malarialrecrudescenceisacommonproblembecauseitisdifficulttocompletelyeradicatemalariaparasitesfrom
the human body. Therefore, the refinement of the anti-malarial performance of fosmidomycin alone or in
combination with another compound is expected to lead to more effective anti-malarial drugs.
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16–20,
Z. mobilis
21, M. tuberculosis
22, and T. maritima
23 have been reported.
However, the crystal structures of the fosmidomycin-target enzyme
PfDXR (when using fosmidomycin as an antimalarial drug) and the
completequaternary(enzyme-NADPH-metal-inhibitor)complexof
DXR have not yet been reported. Here, we report the crystal struc-
tures of PfDXR in the absence and presence of antimalarial drugs.
The complete quaternary complexes revealed that a cis arrangement
oftheoxygenatomsinthehydroxamategroupoftheboundinhibitor
is essential for tight binding of the inhibitor. The results provide
insight for the rational design of more effective PfDXR inhibitors.
Results
Overall structure. In its active form (Lys75 to Ser488), the PfDXR
enzyme isahomo dimerin whicheach subunitcontains anNADPH
molecule and a divalent metal ion. Its molecular mass is approxi-
mately 47 kDa. The crystal structures of PfDXR in an inhibitor-free
ternary complex with NADPH and Mn
21, a fosmidomycin-bound
quaternarycomplexwithNADPHandMg
21(fosmidomycin,Fig.1),
and an FR900098-bound quaternary complex with NADPH and
Mg
21 (FR900098, N-acetyl derivative of fosmidomycin, Fig. 1)
were determined at 1.86-, 1.9-, and 2.15-A ˚ resolutions, respec-
tively. The overall structure of PfDXR is essentially similar to those
of DXRs from other species
16–23. For simplicity, the following
description refers primarily to subunit A of the fosmidomycin
complex. The secondary structure nomenclature is based on that
of E. coli DXR (EcDXR)
16. The subunit of PfDXR consists of two
large domains separated by a cleft containing a deep pocket, a linker
region, and a small C-terminal domain (Fig. 2a). One of the large
domains is responsible for NADPH binding, and the other provides
the groups necessary for catalysis (metal and substrate binding). The
twolargedomainsaresimilarinsize;theNADPH-bindingdomainis
somewhat larger and comprises 154 residues, whereas the catalytic
domain comprises 139 residues.
The NADPH-binding domain comprises residues 77 to 230
(Fig. 2a, blue). The basic element of the secondary structure of this
domainisaseven-strandedb-sheetinthecentreofthedomainthatis
sandwiched by two arrays of three a-helices. The six-stranded par-
allel b-sheet flanked by four a-helices constitutes a characteristic
dinucleotide-binding motif, or Rossmann fold, composed of two
bababunits(b1a1b2a2b3andb5a5b6a6b7).TheNADPH-binding
domain of PfDXR differs from the classic Rossmann fold in that an
additionalabmotif(a3b4)isinsertedafterb3.AnNADPHmolecule
is found in a crevice of the NADPH-binding domain of each of the
twocrystallographicallyindependentsubunitsinanasymmetricunit
of the PfDXR crystal. The binding mode of the NADPH molecule is
quite similar to that observed for EcDXR
16.
The catalytic domain comprises residues 231 to 369 (Fig. 2a,
green). It is an a/b-type structure consisting of five a-helices
Figure 1 | The structures of substrate, product, and inhibitors of PfDXR.
Figure 2 | The three-dimensional structure of PfDXR. a, The subunit
structure of the fosmidomycin-bound quaternary complex of PfDXR. The
NADPH-binding, catalytic, linker, and C-terminal domains are depicted in
blue, green, yellow, and red, respectively. The bound fosmidomycin (black for
carbon) and NADPH (gray for carbon) molecules are shown as ball-and-stick
models. b, The overall structure of PfDXR. One subunit is coloured as in a.
The other subunit is coloured cyan. c, Comparison of the crystal structure of
the inhibitor-free ternary complex of PfDXR (yellow) and that of the inhibitor
(fosmidomycin)-bound quaternary complex of PfDXR (purple).
www.nature.com/scientificreports
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is an open-faced, four-stranded b-sheet with one parallel and two
antiparallel alignments. The loops and helices cover only one side of
the b-sheet. The bound metal ion is found in the bottom of a crevice
in the catalytic domain. The inhibitor molecule, fosmidomycin (or
FR900098), is also found in the crevice of the catalytic domain in the
inhibitor-bound quaternary complex. The binding mode of the
inhibitor molecules will be presented later.
The C-terminal domain comprises residues 396 to 486 (Fig. 2a,
red). This domain is composed of a four-helix bundle structure
(a12–a15). The linker region comprises residues 370 to 395
(Fig. 2a, yellow). This region connects the catalytic domain to the
C-terminal domain, spanning the open face of the catalytic domain.
In the present crystal form, two subunits of an asymmetric unit
formed a homodimer (Fig. 2b), which has also been observed in the
crystalstructuresofDXRsfromotherspecies
16–23.Intersubunitinter-
actions in PfDXR occur primarily along strands of the catalytic
domain b11, thus forming an eight-stranded b-sheet from the
four-stranded b-sheet in the catalytic domains of each subunit.
The linker region also contributes to dimer formation by interacting
with the same region of the other subunit (the antiparallel b-sheet-
like structure formed by Ser387 to Phe391). The NADPH-binding
domains and C-terminal domains of each subunit are located far
from the core of the dimer, and they have minimal interaction with
eachother.TheNADPH-bindingandC-terminaldomainstherefore
appear to be more mobile than the catalytic domains that form the
structural core of the dimer.
A comparison of the crystal structure of the inhibitor-free ternary
complex of PfDXR with those of the inhibitor (fosmidomycin or
FR900098)-bound quaternary complexes of PfDXR showed that
the large cleft between the NADPH-binding and catalytic domains
were closed upon inhibitor binding (Fig. 2c). A closed conformation
was observed for both crystallographically independent subunits of
the inhibitor-bound quaternary complexes. In addition, the dis-
ordered loop region in the inhibitor-free form (residues 291 to
299) was well defined in the inhibitor-bound quaternary complexes.
It has been reported that the known DXR structures can be cate-
gorised into three types of conformations: an open form with the
flexible loop opened (without inhibitor), an open form with the
flexible loop closed (with inhibitor, prepared by soaking), and a
closed form with the flexible loop closed (with inhibitor, prepared
byco-crystallisation)
23. Thecrystal structures of theinhibitor-bound
quaternary complexes of PfDXR correspond to the third type
and represent the first example of a complete closed form with the
flexible loop closed, in that all the components (enzyme-NADPH-
metal-inhibitor) were identified in both subunits of the dimeric
DXR molecule.
Fosmidomycin complex. The fosmidomycin molecule lies in a
crevice of the catalytic domain (Figs. 2, 3a and 3b). The
fosmidomycin-binding cavity consists of three regions: a binding
pocket for the phosphonate moiety of fosmidomycin, a hydro-
phobic patch for the carbon backbone of the inhibitor, and a
binding pocket for the hydroxamate group of the inhibitor. The
phosphonate group of fosmidomycin forms a tightly hydrogen-
bound network with Ser270, Asn311, two water molecules, and
His293, which is disordered in the inhibitor-free form. The carbon
backbone of the inhibitor lies parallel to the indole ring of Trp296
(Fig. 3a). The backbone also interacts with Met298. These
hydrophobic residues are disordered in the inhibitor-free form and
constitute a hydrophobic patch in the fosmidomycin complex.
The hydroxamate group coordinates a Mg
21 ion that is bound by
residues Asp231, Glu233, and Glu315. The side chain of Lys312
is involved in stabilising the side chains of Glu233 and Glu315.
The Mg
21 ion in the inhibitor complex has a distorted trigonal
bipyramidal geometry and binds to three protein ligands and two
inhibitor atoms (Figs. 3a and 3c). The side chains of Asp231(OD1)
and Glu233(OE1), as well as the N-hydroxyl oxygen of
fosmidomycin(O2), are the equatorial ligands, and the axial ligands
are the side chain of Glu315(OE2) and the N-formyl oxygen of
fosmidomycin(O1). Consequently, two oxygen atoms of the hydro-
xamate group of the bound inhibitor adopt a cis arrangement.
Although a few DXR structures that complex with fosmidomycin
have been reported
18–20,22,23, the metal coordination geometry
observed in the present fosmidomycin complex is consistent only
with subunit A of the quaternary (NADPH-Mn
21-fosmidomycin)
complex of M. tuberculosis DXR (MtDXR)
22, in which the electron
density of all components was clearly identified in the active site of
onesubunitofthedimer,althoughtheactivesiteoftheothersubunit
wasempty. The crystalpacking effectof MtDXR probably prevented
the formation of a symmetrical dimer. The failure of the EcDXR and
TmDXR structures
18–20,23 to form well-ordered quaternary com-
plexescouldbeduetounfavourablecrystallisationconditions(acidic
pH) for the binding of the active site metal ion, as the crystals of
PfDXR and MtDXR were obtained at weak basic conditions suitable
for metal binding.
FR900098complex.Inthepresentcrystalstructureanalysis, wealso
successfully determined the FR900098-bound quaternary complex
structure (Figs. 3b and 3d). This is the first crystal structure analysis
of DXR complexed with FR900098, the most potent DXR inhibitor
available. The structure of FR900098 indicates that it is a closely
related derivative of fosmidomycin, and it is approximately twice
as active as fosmidomycin against cultured parasites and in animal
models
5. The structural difference between the inhibitors is the
replacement of the formyl hydrogen of fosmidomycin with a
methyl group in FR900098 (Fig. 1). The overall structure and the
interactions of the inhibitor with the metal and the enzyme are
similar to those observed in the fosmidomycin-bound quaternary
complex. The methyl group of FR900098 is in van der Waals
contact with the side chain of Trp296 and is structurally equivalent
to the C1of the DOXP substrate (Fig. 1). The preferred hydrophobic
interaction between the methyl group of FR900098 and the indole
ring of Trp296 can explain the increased activity against PfDXR
of FR900098 compared with fosmidomycin
5,24. Alternatively,
this interaction might be important for establishing the cis
arrangement of the two oxygen atoms of the hydroxamate group,
inwhichsixatoms(C-N(-O)-C(5O)-C)areinthesameplaneasthe
resonance structures (Figs. 3c and 3d), allowing them to bind to the
active site metal ion. By comparing the structures of the FR900098
andfosmidomycincomplexes,aninducedfitmovementoftheactive
site residues of PfDXR to accommodate the unique methyl group of
FR900098 was suggested for the FR900098 complex (Fig. 3d).
Particularly noteworthy is the approximately 10u rotation of the x2
angle of the indole ring of Trp296. A multiple sequence alignment of
the flexible loop region of DXR (residues 291 to 299 in PfDXR) from
various organisms (Fig. 3e) shows that the buried residues (His293,
Trp296, and Met298 in PfDXR) in the inhibitor-bound structure are
completely conserved, whereas the exposed residues are not well
conserved, except for Pro294 in PfDXR, which may be important
for maintaining the structure of the flexible loop. This multiple
sequence alignment indicates the important role of these buried
residues in the inhibitor/substrate binding associated with loop
closure. It should also be noted that Gly299 in PfDXR is
conserved. The Gly residue may contribute to the flexibility of the
flexible loop as an active site flap.
Discussion
On the basis of the present crystal structure analyses, the structure-
activity relationship studies of fosmidomycin and its analogues
against EcDXR or the in vitro growth inhibition of P. falciparum
24–32
can be re-evaluated with respect tothethree moieties of fosmidomycin
www.nature.com/scientificreports
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bone, and the hydroxamate group. Most reported efforts at synthesis-
ing fosmidomycin analogues involve modifications of the phosphate
and hydroxamate moieties.
Replacement of a phosphonate group by other isosteric groups,
such as a carboxylate (2a and 2b) or a sulphonate (3a and 3b), was
evaluated for reverse hydroxamate analogues of fosmidomycin
26.
The results showed drastically decreased inhibitory activity against
EcDXR and suggest that the tight hydrogen bond network around
the phosphonate group of fosmidomycin or FR900098 revealed
by the present crystal structure analysis is essential for inhibitor
binding. The failure of the carboxylate analogue to inhibit EcDXR
can be explained by a structural difference: a phosphonate has a
pyramidal structure, and a carboxylate has a planar structure. The
failure of the sulphonate analogue to inhibit EcDXR is not as clear as
in the case of a carboxylate analogue. The difference between the
phosphonate and sulphonate groups is that the C-P and P-O bond
lengths are shorter than those of the C-S and S-O bonds. This
difference might prevent the sulphonate group from ideal binding.
On the other hand, the phosphate analogue of FR900098 (4b) (the
Figure 3 | Theinhibitor-bindingsitesofthequaternarycomplexesofPfDXR. a,Fosmidomycincomplex.Thecarbonatomsoffosmidomycin,thefour
buriedwatermolecules,andtheboundMg
21ionareshowninyellow,cyan,andgreen,respectively.b,Stereodiagramsshowingthe |Fo | – |Fc | omitmaps
of bound inhibitors in fosmidomycin (top) and FR900098 (bottom) complexes at 1.8- and 2.15-A ˚ resolutions, respectively. To exclude a model bias,
the structures were refined in the absence of the inhibitor molecules before the map calculation. The amplitude |Fc | and the phase angle calculated from
the partial structure were then used to calculate the |Fo | – |Fc | omit map. The contour levels are 2.5 s (cyan) and 10.0 s(red). c, Schematic drawing
ofthemetalcoordinationsystemobservedinthequaternarycomplexesofPfDXR.BondlengthsareshowninA ˚.d,FR900098complex.Thecarbonatoms
of the FR900098 molecule are shown in magenta. To compare the induced-fit movement of the active site residues upon inhibitor binding, LSQ
fitting wasperformed withrespect tothe 11 atomscommon tothe inhibitors inthe fosmidomycin and FR900098 complexes. The RMSDfor the 11pairs
was 0.50 A ˚. The methyl group of the bound FR900098 molecule is indicated by an arrow head. The fosmidomycin complex is shown in yellow stick
models. e, Multiple sequence alignment of the flexible loop region of DXRs. The abbreviations (GenBank accession numbers) are as follows: Pf
(AAD03739), Plasmodium falciparum DXR; Ec (BAA77848), Escherichia coli DXR; Mt (CAA98375), Mycobacterium tuberculosis DXR; Zm (AAD29659),
Zymomonas mobilis DXR; Tm (AAD35970), Thermotoga maritima DXR. The residue numbers are shown on the right.
www.nature.com/scientificreports
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potent inhibitor of Synechocystis DXR (Ki 5 2 nM) than fosmido-
mycin
27;however,duetothephosphatemoietyinitsstructure,itwas
prone to cleavage and was inactivated by phosphatases in vivo.
Modification of the hydroxamate moiety has been reported by
Rohmer and co-workers
28. The reverse hydroxamate analogues (5a
and 5b) exhibit features—a negatively charged phosphonate group
and a chelating hydroxamate group linked by a carbon backbone
with the same length—similar to those found in fosmidomycin
and FR900098 but have different arrangements in the hydroxamate
group. The reverse hydroxamate showed comparable inhibitory
activities against EcDXR. The present crystal structure analyses
revealed that the cis arrangements of the two oxygen atoms of the
hydroxamate group are necessary for the metal coordination of
the inhibitors. The reverse hydroxamate analogues could bind to
the enzyme active site with similar conformations. Alternatively,
another functional group containing cis oxygen atoms (not only
the functional grops of hydroxamate or reverse hydroxamate) might
have comparable metal coordination ability.
There have been few reports of modification of the length of the
carbon backbone between the hydroxamate moiety and the phos-
phonate. Attempts to shorten the two-methylene spacer for reverse
hydroxamate analogues of fosmidomycin resulted in drastically
decreased inhibitory activity against EcDXR (6a and 6b), whereas
Figure 4 | Summary of the inhibitory activities of fosmidomycin analogues against EcDXR and in vitro growth inhibition of P. falciparum strain 3D7
(or strain K1 for compounds 10a–10c). For compounds 4a and 4b, the relative Ki values against Synechocystis DXR are shown. The relative inhibitory
activitiesoffosmidomycinanalogues,ascomparedwithfosmidomycin,areshownas‘‘111’’(.10),‘‘11’’(1-10),‘‘1’’(1/10-1),and‘‘2’’(,1/10).
www.nature.com/scientificreports
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and 7b)
26. The present crystal structures revealed extended confor-
mations of the bound inhibitors. Shorter compounds were too short
to occupy both the phosphonate binding site and the hydroxamate
binding site. The long spacer of longer compounds prevented them
from efficiently binding to the active site.
The introduction of an electron withdrawing group to the carbon
backbones of fosmidomycin and FR900098 or their reverse hydro-
xamate analogues was recently reported
29–31.Ab-oxa modification
yielded derivatives (8a and 8b) with higher activity against the
P.falciparum3D7strainthanfosmidomycin, whereasac-oxamodi-
fication of reverse hydroxamate analogues resulted in less-active
derivatives (9a and 9b)
29. The present crystal structure analyses
revealed only a hydrophobic interaction between the carbon back-
boneoftheinhibitorsandTrp296,indicatingthattheintroductionof
an oxygen atom to the carbon backbone is not advantageous for
hydrogen bonding to the active site of PfDXR. Instead, the introduc-
tionofanelectronegativeoxygenatommightdecreasethepKa2ofthe
phosphonate group. Thus, the phosphonate group could form a
doubly ionised form, which is more favourable for binding. For
the same reason, an a-aryl substituted fosmidomycin (10a)
30 and
a-halogenated analogues of FR900098 (10b and 10c)
31 showed
higher potency than the reference compounds. Because the carbon
atomatthea-positionoffosmidomycinorFR900098pointstowards
His293 and Met298 on the side chains belonging to the flexible loop
at the active site (Fig. 3a), an a-substituted halogen atom (10b and
10c)couldbeaccommodatedbyaslightinducedfitmovementofthe
flexible loop. However, a bulky functional group in the a-position of
compound 10a appears to be too large to bind; a large-scale induced
fitmovementoftheenzymeactivesitewouldbenecessarytoaccom-
modate the bulky inhibitor. Alternatively, the aromatic ring of the
bulky inhibitor may improve the ability of the inhibitor to cross the
parasitic cell membrane.
To develop new PfDXR inhibitors that have higher inhibitory
activity against the proliferation of P. falciparum, we must consider
two aspects of inhibitors. One is the improvement of the direct
interactions between the bound inhibitor and PfDXR, and the other
is refinement of the pharmacokinetic profile of inhibitors for
clinical use.
With respect to the former issue, analysis of the active sites of
present quaternary complexes revealed the presence of buried and
conserved water molecules in the vicinity of the phosphonate group
of the inhibitors (Figs. 3a and 3c). This finding indicates that the
active site is able to accommodate small functional groups attached
to the phosphonate group. Our prediction is consistent with that for
EcDXR
32. Interestingly, however, it has been reported that bulky
monoesters (phenyl ethyl and 1- or 2-naphthyl ethyl) showed sig-
nificantactivityagainstculturedmalariaparasites
32.Thisunexpected
observationisnotexplainedbythepresentcrystalstructuresbecause
the space at the buried active site is too small to accommodate such
bulky groups if the closed conformation observed in the present
crystal structure analyses is regarded as rigid. One explanation could
bethattherealtargetofthesecompoundsisanotherproteinessential
for the survival of P. falciparum. If not, we must assume that PfDXR
can accommodate a larger functional group attached to the basic
skeleton of fosmidomycin in the active site, as in the case of the
binding of the slightly larger FR900098 by a relatively large-scale
induced fit mechanism. Interdomain flexibility and the existence of
the flexible loop of PfDXR, revealed by the present crystal structure
analyses, would enable this mechanism.
In addition to the efforts to improve the binding affinity of fosmi-
domycin to PfDXR, refinementof its pharmacokinetic profile would
be required for clinical use. Fosmidomycin alone or in combination
with clindamycin shows incomplete eradication of the infection
33.
The eradication rate is expected to rise when the half-life and
bioavailability are improved. With respect to the pharmacokinetic
profiles of fosmidomycin and FR900098, repeated high doses are
required to achieve acceptable cure rates
13–15 because it has been
reported that the oral bioavailabilities of these compounds are rela-
tively poor, with a resorption rate of approximately 30% in rats
34.
This is due to the low lipophilicity of these compounds as a result of
high ionisation of the phosphonate moiety at physiological pH. To
overcome this disadvantage, prodrug approaches were taken that
used bio labile ester moieties that mask the polar phosphonate
moiety of the inhibitors, and promising results were reported (e.g.,
an IC50 value for in vitro growth inhibition of P. falciparum at the
sub-mM level for compound 11)
29. Because the bis(pivaloyloxy-
methyl)ester moiety is removed by an esterase in vivo, the binding
mode of compound 11 would be essentially the same as that of
FR900098 presented here.
Here, we analysed the fosmidomycin and FR900098-bound qua-
ternary complexes of PfDXR. Our study revealed that (i) an intrinsic
flexibility of the PfDXR molecule accounts for the induced-fit move-
ment that accommodates the bound inhibitor in the active site, and
(ii) acis arrangement of the oxygen atoms of the hydroxamate group
oftheboundinhibitorisessentialfortightbindingoftheinhibitorto
theactivesitemetal.TodevelopnewPfDXRinhibitorswithdesirable
pharmacokinetic profiles, both (i) a structure-based inhibitor design
using the present quaternary complex structures as a guide and (ii) a
prodrug approach that masks the polar phosphonate group should
be considered. We believe that our study will serve as a useful guide
for the development of more potent PfDXR inhibitors.
Methods
Overexpression and purification. Expression and purification of PfDXR were
performed as previously described
35. Because the first 30 amino acids of PfDXR
resemble an endoplasmic reticulum signal sequence, and the following 44 amino
acids exhibit the characteristics of a plastidial targetingsequence, the DNA-encoding
residues from Lys75 to Ser488 (C-terminus) of PfDXR were obtained by reverse-
transcription PCR with total RNA from P. falciparum (FCR-3) as the template. The
target DNA was PCR-amplified and cloned into a pQE30 expression plasmid
(QIAGEN).E.coliBL21(DE3)cellsharbouringtheexpressionplasmidweregrownin
LB media at 310 K to an OD600 of 0.6. Overexpression of PfDXR was induced by
0.5 mM IPTG for 20 h at 293 K. After this period, cells were harvested by
centrifugation at 8,000 g and disrupted using ultrasonication on ice. The cell extract
was obtained by centrifugation at 15,000 g and was applied to a 1-ml HisTrap HP
column. PfDXR was eluted with 0.5 M imidazole solution. The PfDXR was further
purified by gel chromatography using a Superdex 200 pg column. The fractions
containing PfDXR were pooled and concentrated to 10 mg/ml using a Centricon-30
microconcentrator (Millipore).
Crystallisation. To obtain the ternary (PfDXR-NADPH-Mn
2) complex, the protein
solution (10 mg/ml PfDXR, 50 mM Tris-HCl pH 7.8, and 2 mM DTT) was mixed
with cofactor solution (50 mM Tris-HCl pH 7.8, 2 mM DTT, 6 mM NADPH, and
4 mM MnCl2) at a volume ratio of 151. Crystallisation was performed by the
hanging-drop method, in which 2 ml of protein solution (5 mg/ml PfDXR, 3 mM
NADPH, and 2 mM Mn
21) was mixed with the same volume of reservoir solution
(0.1 M Tris-HCl pH 8.0, 20% (w/v) PEG3350, and 0.3 M NaCl) and incubated at
293 K. The drops were suspended over 500 ml of reservoir solution in 24-well plates.
To obtain the quaternary (PfDXR-NADPH-Mg
21-fosmidomycin or FR900098)
complexes, the protein solution was mixed with inhibitor solution (50 mM Tris-HCl
pH 7.8, 2 mM DTT, 6 mM NADPH, 4 mM MgCl2, and 4 mM fosmidomycin or
FR900098)atavolumeratioof151.Crystallisationwasperformedusingthehanging-
drop method, in which 2 ml of protein solution (5 mg/ml PfDXR, 3 mM NADPH,
2m MM g
21, and 2 mM fosmidomycin or FR900098) was mixed with the same
volume of reservoir solution (0.1 M Tris-HCl pH 8.0, 20% (w/v) PEG8000, and
0.3 M calcium acetate) and incubated at 293 K. The drops were suspended over 500
ml of reservoir solution in 24-well plates.
X-ray data collection. For data collection under cryogenic conditions, the ternary
complex crystals in a droplet were directly transferred to the harvesting solution
(3 mM NADPH, 2 mM Mn
21, 0.3 M NaCl, 20% (w/v) PEG3350, and 20% (v/v)
glycerol in 0.1 M Tris-HCl pH 8.0) for 1 min. The quaternary complex crystals in a
droplet were transferred directly to a cryoprotectant, Paratone-N (Hampton
Research). The crystals were mounted in nylon loops and flash-cooled in a cold
nitrogen-gas stream at 100 K just prior to data collection. Data were collected by the
rotation method at 100 K using an ADSC Q270 CCD detector with synchrotron
radiation(l51.000 A ˚ onbeamline17AofthePhotonFactory(PF),Tsukuba,Japan)
for the ternary complex and using an ADSC Q210r CCD detector with synchrotron
radiation (l 5 1.000 A ˚ on beamline NW12A of the PF-AR) for the quaternary
complexes. The Laue group and unit-cell parameters were determined using the
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Table S1.
Structure determination. Initial phase determination was performed for the ternary
complex of PfDXR by molecular replacement (MR) using the coordinate set of the
E. coli DXR dimer (PDB code 1ONN), which shares approximately 30% of its amino
acid sequence identity with PfDXR, as a search model. The phase determination was
performed using the AMoRe program
36 from the CCP4 suite
37. Automatic model
building and refinement were performed using the ARP/wARP
38 and REFMAC5
39
programs, and further iterative manual model building and refinement at 1.86 A ˚
resolution wasperformedwith the XtalView
40 andREFMAC5 programs. Therefined
ternary complex model was used for structure determination of the quaternary
(fosmidomycin) complex of PfDXR by the MR method, which was performed using
procedures similar to those described above. The fosmidomycin complex of PfDXR
wasrefinedata1.9-A ˚ resolution.Therefinedfosmidomycincomplexmodelwasthen
usedasatemplateforthestructurerefinementofthequaternary(FR900098)complex
of PfDXR by the D-Fourier method because the crystals of these quaternary
complexes were isomorphous to each other. The FR900098 complex of PfDXR
was refined at a 2.15-A ˚ resolution. Refinement statistics for the ternary and
quaternary complexes of PfDXR are summarised in Table S1. Figures 2a, 2b, 2c,
3a,and 3dwereproducedwith theDSViewerPro program (Accelrys, Inc.). Figure 3b
was produced with the XtalView and Raster3D
41 programs. Least-squares
comparisons of the molecular models were performed using the XtalView program.
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